Study shows increased risk of Guillain-Barré syndrome following vaccination with recombinant zoster vaccine – “an attributable risk of 3 cases per million RZV (Shingrix) doses”.
2 Nov, 2021 | 02:45h | UTCRisk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries – JAMA Internal Medicine (free for a limited period)